Cambridge, MA, United States
Cambridge, MA, United States

Time filter

Source Type

Patent
Ironwood Pharmaceuticals | Date: 2016-09-15

The present patent application discloses at least the compounds according to Formula I or Formula Ib shown below, or pharmaceutically acceptable salts thereof, wherein ring B, J^(B), n, J^(D), J, o, X, R^(C )and R^(A )are as described herein.


2-[1-[(2-Fluorophenyl)methyl]-5-(3-isoxazolyl)-1H-pyrazol-3-yl]-pyrimidine derivatives and related compounds as soluble guanylate cyclase (sGC) stimulators, particularly NO-independent, heme-dependent stimulators, for treating pulmonary hypertension and other diseases.


Patent
Ironwood Pharmaceuticals | Date: 2016-05-31

Compounds of Formula IA and Formula IB are described. They are useful as stimulators of sGC, particularly NO-independent, heme-dependent stimulators. These compounds may be useful for treating, preventing or managing various disorders that are herein disclosed.


Patent
Ironwood Pharmaceuticals | Date: 2017-01-16

Compounds of Formulae I and I are described, which are useful as stimulators of sGC, particularly NO-independent, heme-dependent stimulators. These compounds are also useful for treating, preventing or managing various disorders that are herein disclosed.


Patent
Ironwood Pharmaceuticals | Date: 2017-01-16

Compounds of Formulae I and I are described, which are useful as stimulators of sGC, particularly NO-independent, heme-dependent stimulators. These compounds are also useful for treating, preventing or managing various disorders that are herein disclosed.


Patent
Ironwood Pharmaceuticals | Date: 2017-05-31

Compounds of Formula (I) are described. They are useful as stimulators of sGC, particularly NO-independent, heme-dependent stimulators. These compounds may be useful for treating, preventing or managing various disorders that are herein disclosed.


Patent
Ironwood Pharmaceuticals | Date: 2016-12-07

The present invention provides imidazotriazinone compounds which are inhibitors of phosphodiesterase 9. The present invention further provides processes, pharmaceutical compositions, pharmaceutical preparations and pharmaceutical use of the compounds in the treatment of PDE9 associated diseases or disorders in mammals, including humans.


Patent
Ironwood Pharmaceuticals | Date: 2016-02-26

Compounds of Formula I are described. They are useful as stimulators of sGC, particularly NO-independent, heme-dependent stimulators. These compounds may be useful for treating, preventing or managing various disorders that are herein disclosed.


Patent
Ironwood Pharmaceuticals | Date: 2016-08-24

Compounds of Formulae I and I are described, which are useful as stimulators of sGC, particularly NO-independent, heme-dependent stimulators. These compounds are also useful for treating, preventing or managing various disorders that are herein disclosed.


Patent
Ironwood Pharmaceuticals | Date: 2016-07-21

Compounds of Formulae I and I are described, which are useful as stimulators of sGC, particularly NO-independent, heme-dependent stimulators. These compounds are also useful for treating, preventing or managing various disorders that are herein disclosed.

Loading Ironwood Pharmaceuticals collaborators
Loading Ironwood Pharmaceuticals collaborators